Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : XOMA
Deal Size : $32.0 million
Deal Type : Acquisition
Details : Vidutolimod triggers the body’s innate immune system to attack tumors in combination with other therapies. XOMA has acquired all future potential royalties from commercial sales of vidutolimod, which are tiered from high-single to double digits.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
July 15, 2021
Lead Product(s) : Vidutolimod,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : XOMA
Deal Size : $32.0 million
Deal Type : Acquisition
Lead Product(s) : TGplPTH1-34
Therapeutic Area : Orthopedics/Orthopedic Surgery
Study Phase : Phase II
Sponsor : Avania | Kuros Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
March 03, 2020
Lead Product(s) : TGplPTH1-34
Therapeutic Area : Orthopedics/Orthopedic Surgery
Highest Development Status : Phase II
Sponsor : Avania | Kuros Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable